Author

Vincent Bernard Pagan

The University of Texas MD Anderson Cancer Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:spatial transcriptomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Alens ValentiniD· 1 shared Ana Vilchis Celis· 1 shared André ForjaziD· 1 shared Anirban MaitraiD· 1 shared Ashley L KiemeniD· 1 shared Atul M. DeshpandeiD· 1 shared Benson Chellakkan SelvanesaniD· 1 shared Brian A. PedroiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alens ValentinORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

KRAS-driven metabolic reprogramming of enhanced MFSD2A-mediated lysophosphatidylcholine scavenging promotes survival and progression of pancreatic ductal adenocarcinoma

Yihui Chen, Cason Haffner, Benson Chellakkan Selvanesan, Ranran Wu, Riccardo Ballarò, Ana Vilchis Celis, Mingxin Zuo, LaNisha L. Patterson, Michael Adofo, Jody Vykoukal, Ricardo A. Léon-Letelier, Rongzhang Dou, Soyoung Park, Yining Cai, Daniela Rodriguez-Perera, , Johannes Francois Fahrmann

This study identifies KRAS-driven metabolic reprogramming through MFSD2A-mediated lysophosphatidylcholine scavenging as a driver of PDAC progression and shows that targeting this pathway with edelfosine has anti-cancer effects.

bioRxiv · Oct 6, 2026 · PreprintCancer Biology

Deep Learning Enabled 3D Multi-Omic Analysis Reveals Molecular Signatures of Heterogeneous Response to Chemotherapy in Pancreatic Cancer

André Forjaz, Hengameh Mojdeganlou, Alens Valentin, Meredith Wetzel, Dmitrijs Lvovs, Atul M. Deshpande, Sarah M. Shin, Sujan Piya, Kimal Rajapakshe, Paola Guerrero, Brian A. Pedro, Dimitrios N. Sidiropoulos, Pei-Hsun Wu, Vincent Bernard Pagan, Demystifying Pancreatic Cancer Therapies TeamLab, , Laura DeLong Wood

The paper develops a 3D multi-omic pipeline using deep learning to analyze chemotherapy response in pancreatic cancer, identifying molecular signatures of resistance and fibroblast-cancer interactions.

bioRxiv · Mar 5, 2026 · PreprintCancer Biology